ALT Altimmune Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALT

Price (delayed)

$7.16

Market cap

$507.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.66

Enterprise value

$372.45M

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), ...

Highlights
ALT's revenue has surged by 53% since the previous quarter
The gross profit has soared by 53% from the previous quarter
Altimmune's EPS has increased by 8% YoY but it has decreased by 7% QoQ
Altimmune's net income has decreased by 13% QoQ and by 4.4% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.altimmune.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of ALT
Market
Shares outstanding
70.9M
Market cap
$507.61M
Enterprise value
$372.45M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.98
Price to sales (P/S)
894.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
874.3
Earnings
Revenue
$426,000
EBIT
-$88.41M
EBITDA
-$87.94M
Free cash flow
-$75.86M
Per share
EPS
-$1.66
Free cash flow per share
-$1.42
Book value per share
$3.61
Revenue per share
$0.01
TBVPS
$3.96
Balance sheet
Total assets
$210.64M
Total liabilities
$16.54M
Debt
$0
Equity
$194.1M
Working capital
$197.48M
Liquidity
Debt to equity
0
Current ratio
17.26
Quick ratio
16.39
Net debt/EBITDA
1.54
Margins
EBITDA margin
-20,642%
Gross margin
100%
Net margin
-20,762.2%
Operating margin
-22,518.5%
Efficiency
Return on assets
-47.3%
Return on equity
-52%
Return on invested capital
-153.2%
Return on capital employed
-44.5%
Return on sales
-20,754%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALT stock price

How has the Altimmune stock price performed over time
Intraday
-5.42%
1 week
1.7%
1 month
-21.15%
1 year
29.71%
YTD
-36.36%
QTD
-29.67%

Financial performance

How have Altimmune's revenue and profit performed over time
Revenue
$426,000
Gross profit
$426,000
Operating income
-$95.93M
Net income
-$88.45M
Gross margin
100%
Net margin
-20,762.2%
ALT's revenue has surged by 53% since the previous quarter
The gross profit has soared by 53% from the previous quarter
The net margin has increased by 26% since the previous quarter
The operating margin is up by 26% since the previous quarter

Growth

What is Altimmune's growth rate over time

Valuation

What is Altimmune stock price valuation
P/E
N/A
P/B
1.98
P/S
894.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
874.3
Altimmune's EPS has increased by 8% YoY but it has decreased by 7% QoQ
The P/B is 31% higher than the last 4 quarters average of 1.6 and 17% higher than the 5-year quarterly average of 1.8
The equity has increased by 29% since the previous quarter and by 4.8% year-on-year
ALT's revenue has surged by 53% since the previous quarter

Efficiency

How efficient is Altimmune business performance
Altimmune's return on sales has increased by 26% QoQ
The company's return on invested capital rose by 20% YoY but it fell by 14% QoQ
The return on equity has declined by 18% year-on-year and by 11% since the previous quarter
ALT's ROA is down by 18% YoY and by 12% QoQ

Dividends

What is ALT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Altimmune financials performed over time
Altimmune's current ratio has soared by 53% YoY and by 34% from the previous quarter
ALT's quick ratio has soared by 51% YoY and by 37% QoQ
The debt is 100% smaller than the equity
The equity has increased by 29% since the previous quarter and by 4.8% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.